Development and current status of Antibody-drug conjugate (ADC)

Research output: Contribution to journalArticlepeer-review


Antibody-drug conjugates (ADCs) are expected as next therapeutic antibodies. At present, four ADCs have been approved. ADCs consist from three components, antibody, cytotoxic agents, and linker. In this paper, recent advances of ADC developments are described. From view of antibody development, internarization ability and cancer stromal targeting therapy concept are described. For cytotoxic agents, features of representative agents including radio isotopes are described. Linker technology development for homogeneous ADC preparation is also focused. Representative bioorthogonal reaction for ADC preparation is also included.

Original languageEnglish
Pages (from-to)10-21
Number of pages12
JournalDrug Delivery System
Issue number1
Publication statusPublished - 2019


  • Antibody-drug conjugate
  • Bioorthogonal reaction
  • Cancer stromal targeting therapy
  • Radioimmuno therapy


Dive into the research topics of 'Development and current status of Antibody-drug conjugate (ADC)'. Together they form a unique fingerprint.

Cite this